This product, which has been honoured as a CES 2024 Innovation Awards honouree, simplifies UTI testing with a quick two-minute process. Users download the Vivoo app, use the provided strip for a urine test, and then scan it for instant results. This seamless process allows customers to promptly consult with a doctor and get a prescription if necessary.

What sets Vivoo’s UTI test apart is its status as an app-based medical device that utilises deep learning image processing technology to analyse test results. This approach ensures highly accurate results, reduces the time spent by customers, clarifies potential reading ambiguities, and enables data digitalisation for easy sharing with healthcare professionals through the app.

UTIs are a prevalent health concern globally, affecting around 150 million people annually, with a particularly high incidence among adult women. In the US alone, 60% of women experience UTIs. Vivoo's new product addresses this significant market need by offering an instant, painless, and affordable solution for wellness and diagnostic testing.

Vivoo stands out by eliminating the need for users to send off samples for analysis or losing data after disposing of traditional instant tests. Earlier this year, the company expanded its test portfolio to include vaginal pH tests, catering to the needs of its predominantly female user base, which constitutes 65% of its customers.

The UTI test kit is designed for anyone who suspects they might have a UTI. Starting from Q2 2024, the kits will be available for purchase through Amazon and other outlets, with options for same-day or next-day delivery.

In addition to the testing products, consumers can access a wealth of educational content for free in the Vivoo app.

Miray Tayfun, Co-Founder and CEO of Vivoo, commented: “Our groundbreaking product is set to revolutionise UTI diagnosis with convenient at-home testing, empowered by our user-friendly mobile app. Vivoo goes beyond providing affordable wellness and diagnostic testing; it's a commitment to democratising healthcare, and ensuring global accessibility. With the support of our customers and dedicated investors, we are driving innovation in software as a medical device space.”  

Tim Draper, Founding Partner of Draper Associates, commented: “Vivoo can keep us all informed about our health just by testing our pee. This new UTI test is a major breakthrough allowing people better control of their own health care.”

This announcement follows Vivoo’s previous launch of a 'smart toilet' at CES 2023, which also won an award at the CES Innovations Awards in the Digital Health category. Vivoo is backed by prominent investors, including Draper Associates and Otsuka Pharmaceuticals. The company has reached over 200,000 users, offering eight different at-home tests, and is expanding its global presence through partnerships and retail channels.